• 1
    Carty TJ, Showell HJ, Loose LD, Kadin SB: Inhibition of both 5-lipoxygenase and cyclooxygenase pathways of arachidonic acid metabolism by CP-66,248 (abstract). Arthritis Rheum 31 (Suppl 4): S89, 1988
  • 2
    Moilanen E, Alanko J, Asmawi MZ, Vapaatolo H: CP-66,248, a new antiinflammatory agent, is a potent inhibitor of leukotriene B4 and prostanoid synthesis in human polymorphonuclear leukocytes in vitro. Eicosanoids 1: 3539, 1988
  • 3
    Blackburn WD Jr, Heck LW, Loose LD, Eskra JD, Carty TJ: Inhibition of 5-lipoxygenase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis. Arthritis Rheum 34: 204210, 1991
  • 4
    Sipe JD, Bartle LM, Loose LD: Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen: a possible correlate with clinical acute-phase response. J Immunol 148: 480484, 1992
  • 5
    Otterness IG, Bliven ML, Downs JT, Natoli EJ, Hanson DC: Inhibition of interleukin 1 synthesis by tenidap: a new drug for arthritis. Cytokine 3: 277283, 1991
  • 6
    Pazoles CJ, McNiff P. Laliberte R. Gabel CA: Tenidap acts in vitro as an antagonist of cytokine-induced functions (abstract). Arthritis Rheum 36 (Suppl 9): S109, 1993
  • 7
    Dingle JT: The effect of tenidap on the degradation and repair of human rheumatoid cartilage (abstract). Rev Esp Reumatol 20 (Suppl 1): 8, 1993
  • 8
    Al-Humidan AM, Reilly KM, Leeming MRG, Russell RGG: Tenidap inhibits bone resorption induced by PTH, 1, 25 Vit D3, IL-1, TNF and PGE2 in vitro by mechanisms independent of inhibition of prostaglandin synthesis (abstract). Arthritis Rheum 34 (Suppl 9): S192, 1991
  • 9
    Pelletier JP, McCollum R, Di Battista J, Loose LD, Cloutier JM, Martel-Pelletier J: Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. Arthritis Rheum 36: 15171527, 1993
  • 10
    Dingle JT, Saklatvala J, Hemby RM, Tyler JA, Fell HB, Jubb R: A cartilage catabolic factor. Biochem J 184: 177180, 1979
  • 11
    Pettipher ER, Higgs GA, Henderson B: Interleukin-1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc. Natl Acad Sci U S A 83: 874953, 1986
  • 12
    Harris E Jr: Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 322: 12771289, 1990
  • 13
    Houssiau FA, Devogelaer JP, Van Damme J, Nagant de Deuxchaisnes C, Van Snick J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31: 784788, 1988
  • 14
    Gauldie J, Richards C, Harnish D, Lansdrop P, Baumann H: Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 84: 72517255, 1987
  • 15
    Amos RS, Constable TJ, Crockson RA, Crockson AP, McConkey B: Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. Br Med J 1: 195197, 1977
  • 16
    McConkey B, Crockson RA, Crockson AP: The assessment of rheumatoid arthritis: a study based on measurements of serum acute-phase reactants. Q J Med 41: 115125, 1972
  • 17
    Dixon JS, Bird HA, Sitton NG, Pickup ME, Wright VW: C-reactive protein in the serial assessment of disease activity in rheumatoid arthritis. Scand J Rheumatol 13: 3944, 1984
  • 18
    Dawes PT, Fowler PD, Clarke S, Fisher J, Lawton A, Shadforth MF: Rheumatoid arthritis: treatment which controls the Creactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rheumatol 25: 4449, 1986
  • 19
    Larsen A: The relation of radiographic changes to serum acute-phase proteins and rheumatoid factor in 200 patients with rheumatoid arthritis. Scand J Rheumatol 17: 123129, 1988
  • 20
    Van Leeuwen MA, van Rijswijk MH, van der Heijde DMFM, Te Meerman GJ, van Riel PLCM, Houtman PM, van de Putte LBA, Limburg PC: The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 32 (suppl 3): 913, 1993
  • 21
    Mallya RK, de Beer FC, Beer H, Hamilton EDB, Mace BEW, Pepys M: Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 9: 32243228, 1982
  • 22
    Pepys MB, de Beer FC, Dyck RF, Hind C, Lanham JG, Fagan EA, Maton PN, Starke I, Fox K, Allan R, Hodgson H, Chadwick VS, Hughes GRV, Goldman J, Catovsky D, Galton D, Krikler D, Maseri A, Mallya RK, Berry H, Hamilton EDB, Mace BEW: Clinical measurement of serum C-reactive protein in monitoring and differential diagnosis of inflammatory diseases and tissue necrosis and in the recognition and management of intercurrent infection. Ann N Y Acad Sci 389: 459460, 1982
  • 23
    Ballou SP, Kushner I: C-reactive protein and the acute phase response. Adv Intern Med 37: 313316, 1992
  • 24
    Menkes CJ: Effects of disease-modifying and anti-rheumatic drugs, steroids and non-steroidal anti-inflammatory drugs on acute-phase proteins in rheumatoid arthritis. Br J Rheumatol 32 (suppl 3): 1418, 1993
  • 25
    Leeming MRG: A double-blind randomized comparison of tenidap versus auranofin plus diclofenac in early rheumatoid arthritis (abstract). Rev Esp Reumatol 20 (Suppl 1): 467, 1993
  • 26
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315324, 1988
  • 27
    Steinbrocker O, Traeger CH, Batterman RC: Therapeutic criteria in rheumatoid arthritis. JAMA 140: 659662, 1949
  • 28
    Meenan RF, Gertman PM, Mason JH: Measuring health status in arthritis: the Arthritis Impact Measurement Scales. Arthritis Rheum 23: 146152, 1980
  • 29
    Sipe JD, Gonnerman WA, Loose LD. Knapschaefer G, Franzblau C: Direct binding solid phase ELISA for serum amyloid A (SAA). J Immunol Methods 125: 125135, 1989
  • 30
    Ginsberg JM, Chang BS, Matarese RA, Garella S: Use of single voided urine samples to estimate quantitative proteinuris. N Engl J Med 309: 14531456, 1983
  • 31
    Hirano T, Akira S, Taga T, Kishimoto T: Biological and clinical aspects of IL-6. Immunol Today 11: 443449, 1990
  • 32
    Loose LD, Sipe J, Kirby DS, Kraska AR, Weiner ES, Shanahan WR, Farrow P: Inhibition of acute phase protein production by tenidap: a new antirheumatic agent. Br J Rheumatol 32 (suppl 3): 1925, 1993
  • 33
    Shemesh O, Golbetz H, Kriss JB. Myers BD: Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 28: 830835, 1985
  • 34
    Dubb JW, Stote RM, Familiar RG, Lee K, Alexander F: Effect of cimetidine on renal function in normal man. Clin Pharmacol Ther 24: 7683, 1978
  • 35
    Pesce AJ, First MR: Proteinuria, An Integrated Review. New York, Marcel Dekker, 1979
  • 36
    Petersen PA, Evrin PE, Berggard I: Differentiation of glomerular tubular and normal proteinuria. J Clin Invest 48: 11891197, 1969
  • 37
    Rynes RI: Hydroxychloroquine treatment of rheumatoid arthritis. Am J Med 85: 1822, 1988
  • 38
    Felson DT, Anderson JJ, Meenan RF: Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a metaanalysis of published clinical trials. Arthritis Rheum 35: 11171125, 1992